Neoleukin Therapeutics (NLTX) Downgraded by Zacks Investment Research to Hold

Neoleukin Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Neoleukin Therapeutics Downgraded by Zacks Investment Research on 10/12/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of Neoleukin Therapeutics traded down -$0.05 on Monday, reaching $6.59. 0 shares of the stock traded hands, compared to its average volume of 221300. Shares of Neoleukin Therapeutics were trading at $6.59 on Monday. The firm’s 50 day moving average is $7.20 and its 200 day moving average is $10.43.Neoleukin Therapeutics has a 12 month low of $6.58 and a 12 month high of $17.95. While on yearly highs and lows, Neoleukin Therapeutics’s today has traded high as $6.74 and has touched $6.58 on the downward trend. See More Analyst Rating at: RATING

Neoleukin Therapeutics Earnings and What to expect: 

Neoleukin Therapeutics last posted its quarterly earnings data on August 5th, 2021. The reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.01. Neoleukin Therapeutics has generated ($0.79) earnings per share over the last year (($0.82) diluted earnings per share). Earnings for Neoleukin Therapeutics are expected to decrease in the coming year, from ($1.13) to ($1.37) per share. Neoleukin Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 8th, 2021 based off prior year’s report dates.

Earnings for Neoleukin Therapeutics are expected to decrease in the coming year, from ($1.13) to ($1.37) per share. The P/E ratio of Neoleukin Therapeutics is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Neoleukin Therapeutics is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Neoleukin Therapeutics has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Neoleukin Therapeutics (NLTX) Moving Average Technical Analysis

5 day Moving Average is $6.65 And 5 day price change is -$0.27 (-3.94%)  with average volume for 5 day average is 69,440. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $7.34 and 20 day price change is -$1.08 (-14.08%) and average 20 day moving volume is 150,655. 50 day moving average is $7.20  and 50 day price change is -$0.40 ( -5.72%)  and with average volume for 50 days is : 215,920. 200 day moving average is $10.43  and 200 day price change is -$4.18 (-38.81%)  and with average volume for 200 days is : 255,421.

Other owners latest trading in Neoleukin Therapeutics :

  • On 8/23/2021 shares held by Morgan Stanley were 631,008 which equates to market value of $5.82M and appx 0.00% owners of Neoleukin Therapeutics
  • On 8/17/2021 shares held by Wells Fargo & Company MN were 11,970 which equates to market value of $0.11M and appx 0.00% owners of Neoleukin Therapeutics
  • On 8/17/2021 shares held by Invesco Ltd. were 14,071 which equates to market value of $0.13M and appx 0.00% owners of Neoleukin Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 63.57% for Neoleukin Therapeutics

See More Analyst Rating at: RATING